Personalised blood pressure ranges in type 2 diabetes?

Martin Rutter; Naveed Sattar

doi:10.1016/S2213-8587(18)30002-0

Personalised blood pressure ranges in type 2 diabetes?

Martin Rutter, Naveed Sattar

Division of Diabetes, Endocrinology & Gastroenterology (L5)

Research output: Contribution to journal › Article › peer-review

27 Downloads (Pure)

Abstract

Cardiovascular mortality remains the leading cause of death in people with type 2 diabetes. After publication of the results of the ACCORD blood pressure lowering trial, several guideline committees raised systolic blood pressure (sBP) target levels for most patients with type 2 diabetes from 130 mm Hg to 140 mm Hg.2 This decision was controversial because some, perhaps many, patients might benefit from lower sBP levels.

Original language	English
Journal	The Lancet Diabetes and Endocrinology
Early online date	26 Jan 2018
DOIs	https://doi.org/10.1016/S2213-8587(18)30002-0
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-8587(18)30002-0

Personalized sBP target range_PURE (2)Accepted author manuscript, 69.5 KB

Cite this

@article{36a573131a8842078228dae8de94471a,

title = "Personalised blood pressure ranges in type 2 diabetes?",

abstract = "Cardiovascular mortality remains the leading cause of death in people with type 2 diabetes. After publication of the results of the ACCORD blood pressure lowering trial, several guideline committees raised systolic blood pressure (sBP) target levels for most patients with type 2 diabetes from 130 mm Hg to 140 mm Hg.2 This decision was controversial because some, perhaps many, patients might benefit from lower sBP levels.",

author = "Martin Rutter and Naveed Sattar",

year = "2018",

doi = "10.1016/S2213-8587(18)30002-0",

language = "English",

journal = "The Lancet Diabetes and Endocrinology",